Therapeutic applications of somatostatin analogues

Bibliography

• BRAZEAU P, VALE W, BURGUS R et al.: Hypothalamicpolypeptide that inhibits the secretion of immunore-active pituitary growth hormone. Science (1973) 179:77–79.
   PubMed Web of Science ®Google Scholar
• VEBER DF, HOLLY FW, NUTT RF et al: Highly active cy-clic and bicyclic somatostatin analogs of reduced ring size. Nature (1979) 280:512–514.
   PubMed Web of Science ®Google Scholar
• HEINTGES T, LUTHEN R, NIEDERAU C: Inhibition of exo-crine pancreatic secretion by somatostatin and its ana-logues. Digestion (1994) 55 (Suppl. 0:1–9.
   Google Scholar
• VIRGOLINI I: Mack Forster Award Lecture. Receptor nu-clear medicine: vasointestinal peptide and somatosta-tin receptor scintigraphy for diagnosis and treatment of tumour patients. Eur.J. Clin. Invest. (1997) 27:793–800.
   Google Scholar
• •Report on current knowledge on the clinical use of the title peptides.
   Google Scholar
• EPELBAUM J: SRIF in the central nervous system: physi-ology and pathological modification. Prog. Neurobiol (1986) 27:63–100.
   PubMed Web of Science ®Google Scholar
• EPELBAUM J, DOURNAUD P, FODOR M, VIOLLET C: Theneurobiology of somatostatin. Grit. Rev. Neurobiol. (1994) 8:25–44.
   PubMedGoogle Scholar
• MANDARINO L, STENNER D, BLANCHARD W et al.: Selec-tive effects of SRIF-14, -25, and -28 on in vitro insulin and glucagon secretion. Nature (1981) 291:76–77.
   PubMed Web of Science ®Google Scholar
• MEYERS CA, MURPHY WA, REDDING TW et al.: Synthesis and biological actions of prosomatostatin. Proc. Nati Acad. Sci. USA (1980) 77:6171–6174.
   PubMed Web of Science ®Google Scholar
• FENIUK W, DIMECH J, HUMPHREY P: Characterisationof somatostatin receptors in guinea-pig isolated ileum, vas deferens and right atrium. Br. J. Pharmacol (1993) 110:1156–1164.
   PubMed Web of Science ®Google Scholar
• JACOBS K, AKTORIES K, SCHULTZ G: A nucleotide regu-latory site for SRIF inhibition of adenylyl cyclase in S49 lymphoma cells. Nature (1983) 303:177–178.
   PubMed Web of Science ®Google Scholar
• GILLIES G: Somatostatin: the neuroendocrine story.Trends Pharmacol. Sci. (1997) 18:87–95.
   PubMed Web of Science ®Google Scholar
• REISINE T, BELL GI: Molecular properties of somatosta- tin receptors. Neuroscience (1995) 67:777–790.
   PubMed Web of Science ®Google Scholar
• •Pharmacological and biochemical properties of the cloned somatostatin receptors.
   Google Scholar
• REISINE T, BELL GI: Molecular biology of somatostatin receptors. Endocrinol. Rev. (1995) 16:427–442.
   PubMed Web of Science ®Google Scholar
• ••Review of the different receptor subtypes.
   Google Scholar
• PATEL YC, SRIKANT CB: Somatostatin receptors. Trends Endocrinol. Metab. (1997) 8:398–405.
   PubMed Web of Science ®Google Scholar
• •Review on recent developments.
   Google Scholar
• REISINE T: Somatostatin receptors. Am. J. Physiol. (1995) 269:G813–G820.
   Google Scholar
• •Structure-function analysis of the somatostatin receptors.
   Google Scholar
• BELL GI, YASUDA K, KONG H et al: Molecular biology ofsomatostatin receptors. Ciba Found. Symp. (1995) 190:65–80.
   PubMedGoogle Scholar
• HOYER D, BELL GI, BERELOWITZ M et al.: Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. (1995) 16:86–88.
   PubMed Web of Science ®Google Scholar
• ••Nomenclature for the recombinant somatostatin receptorsaccording to IUPHAR guidelines.
   Google Scholar
• BRUNS C, WECKBECKER G, RAULF F et al: Characterisa-tion of somatostatin receptor subtypes. Ciba Found. Symp. (1995) 190:89–101.
   PubMedGoogle Scholar
• SCHONBRUNN A, GU YZ, DOURNARD P etal: Somatosta-tin receptor subtypes: specific expression and signal-ling properties. Metabolism (1996) 45:8–11.
   PubMed Web of Science ®Google Scholar
• REISINE T: Somatostatin. Cell Mol Neurobiol. (1995)15:597–614.
   Google Scholar
• PATEL YC, GREENWOOD MT, WARSZYNSKA A et al.: All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem. Biophys. Res. Commun. (1994) 198:605–612.
   PubMed Web of Science ®Google Scholar
• BRUNS C, RAULF F, HOYER D et al.: Binding properties of somatostatin receptor subtypes. Metabolism (1996) 45:17–20.
   PubMed Web of Science ®Google Scholar
• YAMADA Y, POST S, WANG K et al.: Cloning and func-tional characterization of a family of human and mouse somatostatin receptors expressed in brain, gas-trointestinal tract, and kidney. Proc. Natl. Acad. Sci. USA (1992) 89:251–255.
   PubMed Web of Science ®Google Scholar
• •First report on molecular cloning of somatostatin receptors.
   Google Scholar
• ROHRER L, RAULF F, BRUNS C et al.: Cloning and charac-terization of a fourth human somatostatin receptor. Proc. Natl. Acad. Sci. USA (1993) 90:4196–4200.
   PubMed Web of Science ®Google Scholar
• LAW SF, WOULFE D, REISINE T: Somatostatin receptoractivation of cellular effector systems. Cell Signal. (1995) 7:1–8.
   PubMed Web of Science ®Google Scholar
• HOYER D, LUBBERT H, BRUNS C: Molecular pharmacol-ogy of somatostatin receptors. Arch. Pharmacol. (1994) 350:441–453.
   Google Scholar
• COY DH, TAYLOR JE: Receptor-specific somatostatinanalogs: correlations with biological activity. Metabo-lism (1996) 45:21–23.
   PubMed Web of Science ®Google Scholar
• YASUDA K, RENS-DOMIANO S, BREDER C et al.: Cloningof a novel somatostatin receptor, SSTR3, coupled to adenylyl cyclase. J. Biol. Chem. (1992) 267:20422–20428.
   PubMed Web of Science ®Google Scholar
• RAYNOR K, MURPHY WA, COY DH et al: Cloned somato-statin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol. Pharmacol. (1993) 43:838–844.
   PubMed Web of Science ®Google Scholar
• ••Potencies of 47 molecules on ssti, sst2 and sst3.
   Google Scholar
• RAYNOR K, O'CARROLL A-M, KONG H et al.: Characteri- sation of cloned somatostatin receptors SSTR4 and SSTR5. Mol. Pharmacol (1993) 44:385–392.
   Google Scholar
• ••Potencies of 47 molecules on sst4 and ssts.
   Google Scholar
• O'CARROLL A-M, LOLAIT SJ, KONIG M, MAHAN LC: Mo- lecular cloning and expression of a pituitary somato-statin receptor with preferential affinity for somatostatin: 28. Mol. Pharmacol. (1993) 44:1278–1278.
   PubMedGoogle Scholar
• •Molecular cloning of sst4.
   Google Scholar
• BRUNO J, XU Y, SONG JF, BERELOWITZ M: Molecular cloning and functional expression of a novel brain so-matostatin receptor. Proc. Natl. Acad. Sci. USA (1992) 89:11151–11155.
   PubMed Web of Science ®Google Scholar
• •Molecular cloning of sst5.
   Google Scholar
• PATEL YC, GREENWOOD M, PANETTA R et al.: The soma-tostatin receptor family. Life Sci. (1995) 57:1249–1265.
   PubMed Web of Science ®Google Scholar
• HUANG Z, PROBSTL A, SPENCER JR et al.: Cyclic hexapeptide analogs of somatostatin containing bridge modifications. Syntheses and conformational analyses. Int. J. PepL Protein Res. (1993) 42:352–365.
   PubMedGoogle Scholar
• BAUER W, BRINER U, DOEPFNER W et al.: SMS 201-995: avery potent and selective octapeptide analogue of so-matostatin with prolonged action. Life Sci. (1982) 31:1133–1140.
   PubMed Web of Science ®Google Scholar
• HOCART SJ, REDDY V, MURPHY WA, COY DH: Three-dimensional quantitative structure-activity relation-ships of somatostatin analogues. 1. Comparative mo-lecular field analysis of growth hormone release-inhibiting potencies. J. Med. Chem. (1995) 38:1974–1989.
   Google Scholar
• OSAPAY G, PROKAI L, KIM H-S et al.: Lanthionine-somatostatin analogs: synthesis, characterization, bio-logical activity, and enzymatic stability studies. J. Med. Chem. (1997) 40:2241–2251.
   PubMed Web of Science ®Google Scholar
• •Thioether-bridged octreotide analogues.
   Google Scholar
• MELACINI G, ZHU Q, OSAPAY G, GOODMAN M: A re-fined model for the somatostatin pharmacophore: conformational analysis of lanthionine-sandostatin analogs. J. Med. Chem. (1997) 40:2252–2258.
   PubMed Web of Science ®Google Scholar
• HE Y-B, HUANG Z, RAYNOR K et al: Synthesis and con-formations of somatostatin related cyclic hexapep-tides incorporating specific alpha-methylated and beta-methylated residues. J. Am. Chem. Soc. (1993) 115:8066–8072.
   Web of Science ®Google Scholar
• HOCART SJ, JAIN R, MURPHY WA et al.: Potent antago-nists of somatostatin: synthesis and biology. J. Med. Chem. (1998) 41:1146–1154.
   PubMed Web of Science ®Google Scholar
• •Development of the first highly potent antagonist.
   Google Scholar
• SCHALLY AV: Oncological applications of somatostatinanalogues. Cancer Res. (1988) 48:6977–6985.
   PubMed Web of Science ®Google Scholar
• SETYONO-HAN B, HENKELMAN MS, FOEKENS JA, KLIJNJGM: Direct inhibitory effects of somatostatin (ana-logues) on the growth of human breast cancer cells. Cancer Res. (1987) 47:1566–1570.
   PubMed Web of Science ®Google Scholar
• •Inhibition of GH release and tumour growth.
   Google Scholar
• PINSKI J, SCHALLY AV, HALMOS G et al.: Somatostatin analog RC-160 inhibits the growth of human osteosar-comas in nude mice. Int. J. Cancer (1996) 65:870–874.
   PubMed Web of Science ®Google Scholar
• •Inhibition of GH release and tumour growth.
   Google Scholar
• QIN Y, ERTL T, GROOT K et al.: Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic can-cer cells in vitro and intracellular production of cyclic adenosine monophosphate. Int. J. Cancer (1995) 60:694–700.
   PubMed Web of Science ®Google Scholar
• SHIMON I, TAYLOR JE, DONG JZ et al.: Somatostatin re-ceptor subtype specificity in human fetal pituitary cul-tures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolac-tin regulation. J. Clin. Invest. (1997) 99:789–798.
   Google Scholar
• CARON P, MORANGE-RAMOS I, COGNE M, JAQUET P: Three years' follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J. Clin. En-docrinol. Metab. (1997) 82:18–22.
   PubMed Web of Science ®Google Scholar
• SHIMON I, YAN X, TAYLOR JE et al.: Somatostatin recep-tor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J. Clin. Invest. (1997) 100:2386–2392.
   PubMed Web of Science ®Google Scholar
• ROSSOWSKI WJ, COY DH: Specific inhibition of rat pan-creatic insulin or glucagon release by receptor-selective somatostatin analogs. Biochem. Biophys. Res. Commun. (1994) 205:341–346.
   PubMed Web of Science ®Google Scholar
• LIAPAKIS G, HOEGER C, RIVIER J, REISINE T: Develop-ment of a selective agonist at the somatostatin recep-tor subtype sstr 1 . J. PharmacoL Exp. Ther. (1996) 276:1089–1094.
   PubMed Web of Science ®Google Scholar
• BUSCAIL L, ESTEVE J-P, SAINT-LAURENT N et al: Inhibi-tion of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl. Acad. Sci. USA (1995) 92:1580–1584.
   PubMed Web of Science ®Google Scholar
• YUMI K, FAGIN JA, YAMASHITA M et al: Direct effects ofsomatostatin analog octreotide on insulin-like growth factor-I in the arterial wall. Lab. Invest. (1997) 76:329–338.
   PubMed Web of Science ®Google Scholar
• SERRI 0, BRAZEAU P, KACHRA Z, POSNER B: Octreotideinhibits insulin-like growth factor-I hepatic gene ex-pression in the hypophysectomized rat: Evidence for a direct and indirect mechanism of action. Endocrinology (1992) 130: 1816-1821.
   Google Scholar
• BECH K: Effect of somatostatin on histamine-stimulated gastric acid and pepsin secretion in dogs. Scand.J. Gastroenterol. (1986) 215:662–668.
   Google Scholar
• LARSSON LN, GOLTERMANN N, MAGISTRIS L eta].: Soma-tostatin cell processes as pathways for paracrine se-cretion. Science (1979) 205:1393–1395.
   Google Scholar
• PAYNE CG, GERBER JG: Differential effects of somato-statin and prostaglandins on gastric histamine release to pentagastrin. J. Pharmacol. Exp. Ther. (1992) 263:520–526.
   PubMed Web of Science ®Google Scholar
• BLOOM SR, MORTIMER CH, THORNER MO: Inhibition ofgastrin and gastric-acid secretion by growth-hormone release inhibiting hormone. Lancet (1974) 2:1106–1109.
   PubMed Web of Science ®Google Scholar
• PARK J, CHIBA T, YAMADA T: Mechanisms for direct in-hibition of canine gastric parietal cells by somatosta-tin. J. Biol. Chem. (1987) 262:14190–14196.
   PubMedGoogle Scholar
• BRUNO JF, XU Y, SONG J, BERELOWITZ M: Tissue distri-bution of somatostatin receptor subtype messenger ri-bonucleic acid in the rat. Endocrinology (1993) 133:2561–2567.
   PubMed Web of Science ®Google Scholar
• LLOYD KC, AMIRMOAZZAMI S, FRIEDIK F et al.: Somato-statin inhibits gastrin release and acid secretion by ac-tivating sst2 in dogs. Am. J. Physiol. (1997) 272:G1481–G1488.
   Google Scholar
• VALE W, RIVIER J, LING N, BROWN M: Biologic and im-munologic activities and applications of somatostatin analogs. Metabolism (1978) 27:1391–1401.
   PubMed Web of Science ®Google Scholar
• ROSSOWSKI WJ, COY DH: Potent inhibitory effects of atype four receptor-selective somatostatin analog on rat insulin release. Biochem. Biophys. Res. Commun. (1993) 197:366–371.
   PubMed Web of Science ®Google Scholar
• •Strong inhibitor of insulin secretion.
   Google Scholar
• MASCARDO R, SHELINE P: Somatostatin inhibits rapidcentrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology (1982) 111:1394–1396.
   PubMed Web of Science ®Google Scholar
• ROBBINS RJ: Somatostatin and cancer. Metabolism(1996) 45:98–100.
   PubMed Web of Science ®Google Scholar
• LAMBERTS S, DE HERDER WW, VAN KOETSVELD PM et al.:Somatostatin receptors: clinical implications for en-docrinology and oncology. Ciba Found. Symp. (1995) 190:222–236.
   Google Scholar
• •Radiolabelled somatostatins for radioligand surgery.
   Google Scholar
• MAULARD C, RICHAUD P, DROZ JP eta].: Phase I-II studyof the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother. Pharma-col. (1995) 36:259–262.
   Google Scholar
• LIAPAKIS G, FITZPATRICK D, HOEGER C et al: Identifica-tion of ligand binding determinants in the somatosta-tin receptor subtypes 1 and 2. J. Biol. Chem. (1996) 271:20331–20339.
   PubMedGoogle Scholar
• •First highly-active and selective ssti agonist.
   Google Scholar
• KERI G, ERCHEGYI J, HORVATH A et al.: A tumor- selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc. Natl. Acad. ScL USA (1996) 93:12513–12518.
   PubMed Web of Science ®Google Scholar
• •Anticancer drug candidate without inhibition of GH release.
   Google Scholar
• KOLBECK W, GOODMAN M, OSAPAY G: Preparation of lanthionine-bridged peptides. Pending US Patent Appli-cation Chem. Abstr. (1993) 119:203861.
   Google Scholar
• •Synthesis of thioether-bridged bioactive peptides.
   Google Scholar
• ZHENG H, FINK D, LI H et al: In vitro antineoplastic ac-tivity of novel lanthionine-containing peptide. Clin. Cancer Res. (1997) 3:1323–1330.
   PubMed Web of Science ®Google Scholar
• VEBER DF, FREIDINGER RM, PERLOW DS et al.: A potent cyclic hexapeptide analogue of somatostatin. Nature (1981) 292:55–58.
   PubMed Web of Science ®Google Scholar
• HUANG Z, HE Y-B, RAYNOR K eta].: Main chain and side chain chiral methylated somatostatin analogs: Synthe-ses and conformational analyses. J. Am. Chem. Soc. (1992) 114:9390–9401
   Google Scholar
• HIRSCHMANN R, NICOLAOU KC, PIETRANICO S et al: Nonpeptidal peptidomimetics with a 13-D-glucose scaf-folding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P agonist. J. Am. Chem. Soc. (1992) 114:9217–9218.
   Google Scholar
• •First non-peptide somatostatin analogues.
   Google Scholar
• HIRSCHMANN R, NICOLAOU K, PIETRANICO S et al: De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing p-D-glucose as a novel scaffolding. J. Am. Chem. Soc. (1993) 115:12550–12568.
   Web of Science ®Google Scholar
• DAMOUR D, BARREAU M, BLANCHARD J et al: Design, synthesis and binding affinities of novel non-peptide mimics of somatostatin/sandostatin. Bioorg. Med. Chem. Lett. (1996) 6:1667–1672.
   Web of Science ®Google Scholar
• BEUSEN DD, ZABROCKI J, SLOMCZYNSKA U et al: Con-formational mimicry: synthesis and solution confor-mation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate. Bio-polymers (1995) 36:181–200.
   PubMed Web of Science ®Google Scholar
• FRIES JL, MURPHY WA, SUEIRAS-DIAZ J, COY DH: Soma-tostatin antagonist analog increases Gil, insulin, and glucagon release in the rat. Peptides (1982) 3:811–814.
   PubMed Web of Science ®Google Scholar
• BASS RT, BUCKWALTER BL, PATEL BP et al: Identifica-tion and characterization of novel somatostatin an-tagonists. Mol. Pharmacol. (1996) 50:709–715.
   PubMed Web of Science ®Google Scholar
• REUBI JC, SCHAER JC, WASER B, MENGOD G: Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. (1994) 54:3455–3459.
   PubMed Web of Science ®Google Scholar